Germany Oncology Therapeutics Market Report 2022 to 2030

Germany Oncology Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Germany Oncology Therapeutics Market will reach a value of $11 Bn from $6.6 Bn in 2022, growing at a CAGR of 6.6% during 2022-30. The Oncology Therapeutics Market in Germany is dominated by a few domestic pharmaceutical companies such as Bristol Myers Squibb, Boehringer Ingelheim, and CureVac. The Oncology Therapeutics Market in Germany is segmented into different types of cancer and different therapy type. The major risk factors associated with cancer are diet, alcohol, tobacco, air pollution, and physical inactivity. The demand for Germany Oncology Therapeutics is increasing on account of the rise in initiatives taken by the Government of the country.

ID: IN10DEPH042 CATEGORY: Pharmaceuticals GEOGRAPHY: Germany AUTHOR: Dr. Vishwa Modhia

Buy Now

Germany Oncology Therapeutics Market Analysis Summary

By 2030, it is anticipated that the Germany Oncology Therapeutics Market will reach a value of $11 Bn from $6.6 Bn in 2022, growing at a CAGR of 6.6% during 2022-30.

Germany is a developed, high-income country in the centre of Western Europe. In Germany, approximately 502,655 new cancer cases were identified in 2019. Cancer is the second leading cause of death, accounting for 25% of all deaths. Lung cancer is the second leading cause of death in males, after cardiovascular disease, accounting for 6.5 % of all-cause mortality. There were around 267,730 male cases and 234,925 female cases. Approximately half of the cases (71,375) were diagnosed in the breast, the prostate (68,579), the colon (58,967), or the lung (59,221). The absolute number of new cancer cases grew by 12% for men and 5% for women between 2009 and 2019. In Germany, around 1.6 Mn people have had cancer that was diagnosed during the last five years.

According to the German Cancer Research Center (DKFZ), at least 37% of all new cancer cases in Germany can be related to avoidable or at least changeable risk factors such as smoking, nutrition difficulties, and obesity. Smoking is responsible for around 19% of all annual incident cancer cases in Germany. Germany's government spent 12.8 % of its GDP on healthcare in 2020.

Germany Oncology Therapeutics Market Analysis

Market Dynamics

Market Growth Drivers Analysis

In the German health system, radiation oncology is a readily available resource. According to the German Society for Radiation Oncology, there are currently over 700 institutes in Germany that provide radiotherapy services. Many alternative cancer treatments are available in Germany, including photodynamic laser therapy, hyperthermia, and Galvano therapy. Alternative cancer treatments have grown in popularity in Germany in recent years. Germany has a low structural unemployment rate and an extensive apprenticeship programme. These aspects could boost German Oncology Therapeutics Market.

Market restraints

Total financed pre-launch R&D costs in Germany were reported to range from $161 Mn to $4.54 Bn (2019 US dollars). Anticancer drugs had the highest therapeutic area-specific estimates (between $944 Mn and $5.4 Bn). Despite immigration, the German labour force is expected to shrink beginning in 2020. These factors may deter new entrants into the German Oncology Therapeutics Market.

Competitive Landscape

Key Players

Merck KGaA: Merck KGaA is a German multinational pharmaceutical company that specializes in the development and production of cancer therapeutics, including chemotherapy drugs and immunotherapies
Bayer AG: Bayer AG is a German multinational pharmaceutical and life sciences company that develops and produces a range of cancer therapeutics, including chemotherapy drugs and targeted therapies
Boehringer Ingelheim: Boehringer Ingelheim is a German multinational pharmaceutical company that specializes in the development of cancer therapeutics, including targeted therapies and immunotherapies
CureVac: CureVac is a German biotechnology company that focuses on the development of novel mRNA-based therapies for a range of diseases, including cancer. The company is currently developing several mRNA-based cancer immunotherapies

Notable Recent Deals

March 2023: Due to pricing pressures, Bristol-Myers Squibb (BMS) has chosen not to offer its cancer medicine Opdualag (nivolumab and relatlimab) in Germany. The European Commission initially authorised the medication in September 2022 as a first-line option for advanced melanoma in adults and adolescents aged 12 years and older. This was based on an exploratory examination of data from a phase 2/3 trial, which revealed that the fixed-dose combination more than doubled the median progression-free survival when compared to nivolumab monotherapy, which was previously considered the gold standard of care.

January 2023: 3T Biosciences and Boehringer Ingelheim announced a strategic collaboration and licencing agreement to study and develop next-generation cancer therapies to address large unmet patient needs. The collaboration will bring together 3T Biosciences' best-in-class 3T-TRACE (T-Cell Receptor Antigen and Cross-Reactivity Engine) discovery platform and Boehringer Ingelheim's two-pronged research strategy that combines cancer cell-directed and immune cell-targeting compounds, bolstering the company's pipeline.

Healthcare Policies and Reimbursement Scenarios

In Germany, the regulatory authority responsible for the approval and regulation of therapeutic products, including cancer therapeutics, is the Federal Institute for Drugs and Medical Devices (BfArM). The German government also runs a special fund known as the Innovation Fund, which funds innovative healthcare projects such as the development of novel cancer treatments.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Oncology Therapeutics Segmentation

By Application (Revenue, USD Billion):

Blood Cancer
?Colorectal Cancer
Gastrointestinal Cancer
Gynaecologic Cancer
Breast Cancer
Lung Cancer
Prostate Cancer
?Others

By Drugs (Revenue, USD Billion):

Revlimid
Avastin
Herceptin
Rituxan
Opdivo
Gleevec
Velcade
Imbruvica
Ibrance
Zytiga
Alimta
Xtandi
Tarceva
Perjeta
Temodar
Others

By Therapy (Revenue, USD Billion):

Chemotherapy
Targeted Therapy
Immunotherapy
Hormonal Therapy
Others

By Route of Administration (Revenue, USD Billion):

Oral
Parenteral
Others

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
?Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.